News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,395 Results
Type
Article (39489)
Company Profile (281)
Press Release (648625)
Section
Business (204801)
Career Advice (1998)
Deals (35468)
Drug Delivery (88)
Drug Development (81076)
Employer Resources (168)
FDA (16200)
Job Trends (14853)
News (346310)
Policy (33020)
Tag
Academia (2555)
Alliances (49309)
Alzheimer's disease (1227)
Approvals (16125)
Artificial intelligence (125)
Bankruptcy (352)
Best Places to Work (11550)
Biotechnology (200)
Breast cancer (116)
Cancer (1025)
Cardiovascular disease (85)
Career advice (1668)
Cell therapy (215)
Clinical research (64310)
Collaboration (361)
Compensation (188)
COVID-19 (2545)
C-suite (87)
Data (1018)
Diabetes (152)
Diagnostics (6143)
Earnings (85095)
Employer resources (146)
Events (109880)
Executive appointments (275)
FDA (16696)
Funding (322)
Gene therapy (169)
GLP-1 (576)
Government (4594)
Healthcare (18815)
Infectious disease (2627)
Inflammatory bowel disease (104)
Interviews (310)
IPO (16326)
Job creations (3648)
Job search strategy (1426)
Layoffs (413)
Legal (7917)
Lung cancer (160)
Manufacturing (166)
Medical device (13229)
Medtech (13234)
Mergers & acquisitions (19192)
Metabolic disorders (397)
Neuroscience (1486)
NextGen Class of 2024 (6522)
Non-profit (4507)
Northern California (1397)
Obesity (232)
Opinion (179)
Patents (98)
People (56450)
Phase I (19944)
Phase II (28305)
Phase III (21160)
Pipeline (407)
Postmarket research (2565)
Preclinical (8486)
Radiopharmaceuticals (235)
Rare diseases (200)
Real estate (5919)
Regulatory (21748)
Research institute (2324)
Resumes & cover letters (349)
Southern California (1244)
Startups (3576)
United States (12863)
Vaccines (552)
Weight loss (171)
Date
Today (193)
Last 7 days (980)
Last 30 days (3636)
Last 365 days (35515)
2024 (31950)
2023 (40169)
2022 (51326)
2021 (55916)
2020 (54367)
2019 (46940)
2018 (35322)
2017 (32267)
2016 (31713)
2015 (37758)
2014 (31487)
2013 (26504)
2012 (28711)
2011 (29398)
2010 (27478)
Location
Africa (728)
Arizona (191)
Asia (37266)
Australia (6101)
California (3141)
Canada (1247)
China (235)
Colorado (139)
Connecticut (140)
Europe (80044)
Florida (433)
Georgia (110)
Illinois (333)
Indiana (190)
Kansas (96)
Maryland (558)
Massachusetts (2493)
Michigan (151)
Minnesota (266)
New Jersey (908)
New York (914)
North Carolina (686)
Northern California (1397)
Ohio (133)
Pennsylvania (806)
South America (1102)
Southern California (1244)
Texas (427)
Utah (87)
Washington State (347)
688,395 Results for "sobi canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Enable Injections Announces Agreement with Sobi® to Develop and Distribute Aspaveli® in Combination with enFuse® in Sobi Territories
September 13, 2024
·
3 min read
Press Releases
Sobi to present new data across its immunology portfolio at the ACR Convergence 2024
November 8, 2024
·
6 min read
Policy
European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Sobi® announced the European Commission has granted Marketing Authorisation for ALTUVOCT™, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity.
June 19, 2024
·
7 min read
Genetown
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology Annual Meeting taking place in Chicago from May 31 – June 4, 2024.
May 24, 2024
·
8 min read
Policy
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced that the US Food and Drug Administration has granted Fast Track designation to emapalumab-lzsg being investigated as a potential therapeutic option in patients with Macrophage Activation Syndrome.
May 24, 2024
·
5 min read
Policy
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
June 20, 2024
·
2 min read
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A.
April 26, 2024
·
6 min read
Press Releases
Inagene Diagnostics Inc. Launches Canada’s Most Comprehensive Genetic Test for Cardiovascular Medications, Highlighting Major Gaps in Heart Medication Awareness
October 25, 2024
·
3 min read
BioSyent In-Licenses Endocrinology Product for Canada
BioSyent Inc. is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada.
June 12, 2024
·
2 min read
Press Releases
OBIO® and CATTI Collaborate to Boost Canada’s Biomanufacturing Capacity for Advanced Therapies
November 4, 2024
·
3 min read
1 of 68,840
Next
